Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study

Rapport Therapeutics announced Tuesday that its investigational oral drug has cleared a mid-stage trial for bipolar mania. The drug works by dialing down the effect of AMPA receptors, and the successful trial allows for registrational studies to begin next year, according to Endpoints News.

Separately, Mabwell will present Phase II clinical data regarding its Nectin-4-targeting antibody-drug conjugate, 9MW2821, at the 2026 European Society for Medical Oncology (ESMO) Congress. The study evaluated the efficacy and safety of the drug as a monotherapy or in combination with a PD-1 monoclonal antibody in patients with locally advanced or metastatic triple-negative breast cancer who were previously treated with a Topo I ADC.

As of April 10, 2026, data from 60 efficacy-evaluable patients showed an objective response rate of 30.0% and a disease control rate of 80.0%. The Vietnam Investment Review reports that the median progression-free survival was 3.7 months and the median duration of response was 8.7 months, with median overall survival not yet mature. No new safety signals were observed during the follow-up period.

Brief written by urgent.news from Endpoints News, Vietnam Investment Review — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.